Qi Biodesign, a company involved in genome-editing technologies, announced that it has completed a $75 million funding round, which includes seed funding and Series Pre-A and Series A stages.
Beijing Medical and Health Care Industry Investment Fund led the round, with additional participation from Beijing Changping Technology Innodevelop Group, Mingzhe Capital and returning investor CD Capital. ...
